Title: Intestinal Claudin-7 deficiency impacts the intestinal microbiota in mice with colitis
Version: 1 Date: 24 Sep 2021
Reviewer's report:
The author performed some of the suggested changes. However, some important points and easy
to change aspects remain unaddressed.
1. The animal naming system was not changed. Although a previous publication used the naming
system, it does not mean it is correct and need to be consistent with. The authors indicated
that they compared Cldn7 fl/fl CreERT2 and Cldn7 fl/fl CreW group. What is the CreW mice?
Pubmed search did not turn out anything.
2. It has been reported that tamoxifen treatment in VilCreERT2 can cause genome toxicity and
impair stem cell function (Bohin, et al, Stem Cell Reports 2018). How does the author exclude
that the phenotypes reported in this manuscript is not caused by this tamoxifen-VilCreERT2
effect, rather than specific effect of Cldn7 deletion? Cldn7 fl/fl VilCreERT2 and Cldn7 +/+
VilCreERT2 mice need to be compared.
3. For the microbiome figures. The naming was not changed. If the graphing package does not
allow more characters used, either another graphing package need to be used, or the graphs need
to be post processed using software such as CorelDRAW or Adobe Illustrator. The fonts remain
to be very small to see.
4. The authors claim that some of the DSS phenotype has been published previously. Does this
mean Fig 1. is basically replicating previous results?
5. For Muc2 and Bacterial translocation studies, only 3 mice with large variation between
animals are shown. This is not convincing. More animals are needed for these studies.
6. The fraction of Muc2 positive cell issue is not resolved. Can number of Muc2 positive cell
per total epithelial cell be counted in colon in all groups of mice.
7. New Fig. 3 and 4, fonts are still too small to see.
8. New Fig. 5-7. Although some more detailed characterization of microbiome is performed,
it still does not address if the microbiome change is a driver for Cldn7 to impact DSS induced
disease, or independent events. How does antibiotic treatment affect DSS induced epithelial
damage in control and induced Cldn7 KO mice?
9. Writing can be improved across the manuscript to make it clear and accurate. For example,
the claudin-7 KO is tamoxifen-induced KO, this should be specified in the manuscript.
Title: Intestinal Claudin-7 deficiency impacts the intestinal microbiota in mice with colitis
Version: 1 Date: 24 Sep 2021
Reviewer's report:
The author performed some of the suggested changes. However, some important points and easy
to change aspects remain unaddressed.
1. The animal naming system was not changed. Although a previous publication used the naming
system, it does not mean it is correct and need to be consistent with. The authors indicated
that they compared Cldn7 fl/fl CreERT2 and Cldn7 fl/fl CreW group. What is the CreW mice?
Pubmed search did not turn out anything.
2. It has been reported that tamoxifen treatment in VilCreERT2 can cause genome toxicity and
impair stem cell function (Bohin, et al, Stem Cell Reports 2018). How does the author exclude
that the phenotypes reported in this manuscript is not caused by this tamoxifen-VilCreERT2
effect, rather than specific effect of Cldn7 deletion? Cldn7 fl/fl VilCreERT2 and Cldn7 +/+
VilCreERT2 mice need to be compared.
3. For the microbiome figures. The naming was not changed. If the graphing package does not
allow more characters used, either another graphing package need to be used, or the graphs need
to be post processed using software such as CorelDRAW or Adobe Illustrator. The fonts remain
to be very small to see.
4. The authors claim that some of the DSS phenotype has been published previously. Does this
mean Fig 1. is basically replicating previous results?
5. For Muc2 and Bacterial translocation studies, only 3 mice with large variation between
animals are shown. This is not convincing. More animals are needed for these studies.
6. The fraction of Muc2 positive cell issue is not resolved. Can number of Muc2 positive cell
per total epithelial cell be counted in colon in all groups of mice.
7. New Fig. 3 and 4, fonts are still too small to see.
8. New Fig. 5-7. Although some more detailed characterization of microbiome is performed,
it still does not address if the microbiome change is a driver for Cldn7 to impact DSS induced
disease, or independent events. How does antibiotic treatment affect DSS induced epithelial
damage in control and induced Cldn7 KO mice?
9. Writing can be improved across the manuscript to make it clear and accurate. For example,
the claudin-7 KO is tamoxifen-induced KO, this should be specified in the manuscript.
Please review this paper.
user
Title: Intestinal Claudin-7 deficiency impacts the intestinal microbiota in mice with colitis
Version: 1 Date: 24 Sep 2021
Reviewer's report:
The author performed some of the suggested changes. However, some important points and easy
to change aspects remain unaddressed.
1. The animal naming system was not changed. Although a previous publication used the naming
system, it does not mean it is correct and need to be consistent with. The authors indicated
that they compared Cldn7 fl/fl CreERT2 and Cldn7 fl/fl CreW group. What is the CreW mice?
Pubmed search did not turn out anything.
2. It has been reported that tamoxifen treatment in VilCreERT2 can cause genome toxicity and
impair stem cell function (Bohin, et al, Stem Cell Reports 2018). How does the author exclude
that the phenotypes reported in this manuscript is not caused by this tamoxifen-VilCreERT2
effect, rather than specific effect of Cldn7 deletion? Cldn7 fl/fl VilCreERT2 and Cldn7 +/+
VilCreERT2 mice need to be compared.
3. For the microbiome figures. The naming was not changed. If the graphing package does not
allow more characters used, either another graphing package need to be used, or the graphs need
to be post processed using software such as CorelDRAW or Adobe Illustrator. The fonts remain
to be very small to see.
4. The authors claim that some of the DSS phenotype has been published previously. Does this
mean Fig 1. is basically replicating previous results?
5. For Muc2 and Bacterial translocation studies, only 3 mice with large variation between
animals are shown. This is not convincing. More animals are needed for these studies.
6. The fraction of Muc2 positive cell issue is not resolved. Can number of Muc2 positive cell
per total epithelial cell be counted in colon in all groups of mice.
7. New Fig. 3 and 4, fonts are still too small to see.
8. New Fig. 5-7. Although some more detailed characterization of microbiome is performed,
it still does not address if the microbiome change is a driver for Cldn7 to impact DSS induced
disease, or independent events. How does antibiotic treatment affect DSS induced epithelial
damage in control and induced Cldn7 KO mice?
9. Writing can be improved across the manuscript to make it clear and accurate. For example,
the claudin-7 KO is tamoxifen-induced KO, this should be specified in the manuscript.
assistant